Ownership and insider activity for Biomea Fusion, Inc. (BMEA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; an...
Price
| Price | $1.74 |
| Market Cap | $126M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $239000 | $61.7M | $145.7M | $111.9M | $176.9M | $58.3M | $55.8M |
| Short-term Investments | 0 | 0 | $27.8M | $1.1M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $265000 | $62.2M | $176.6M | $117.8M | $179.2M | $68.3M | $58.0M |
| Property, Plant & Equipment | 0 | $291000 | $5.7M | $8.0M | $14.9M | $10.6M | $153000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $265000 | $62.5M | $185.7M | $129.3M | $199.9M | $79.9M | $58.6M |
| Accounts Payable | $271000 | $727000 | $1.3M | $6.8M | $6.9M | $12.9M | $3.2M |
| Short-term Debt | 0 | $36000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $286000 | $1.6M | $4.6M | $19.1M | $22.9M | $21.7M | $11.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $286000 | $57.4M | $6.9M | $20.8M | $30.7M | $28.4M | $29.0M |
| Retained Earnings | -$2.9M | -$8.2M | -$49.7M | -$131.6M | -$248.8M | -$387.3M | -$449.0M |
| Total Equity | -$21000 | $5.2M | $178.8M | $108.5M | $169.2M | $51.6M | $29.6M |
| Total Debt | 0 | $259000 | $2.9M | $2.3M | $10.3M | $8.8M | $1.6M |
| Net Debt | -$239000 | -$61.4M | -$170.7M | -$110.8M | -$166.6M | -$49.5M | -$54.2M |
| Working Capital | -$21000 | $60.6M | $171.9M | $98.7M | $156.3M | $46.7M | $46.9M |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 3.47 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -13.01 |
Profitability
| Return on Equity | -171.19% |
| Return on Invested Capital | -212.95% |
| Return on Assets | -88.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · CAMP · CBUS · GUTS · IMUX · PMVP
Explore sector: Healthcare · Biotechnology
More sections of BMEA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks